AU2003293376A1 - Anti-angiogenic compounds and their use in cancer treatment - Google Patents

Anti-angiogenic compounds and their use in cancer treatment

Info

Publication number
AU2003293376A1
AU2003293376A1 AU2003293376A AU2003293376A AU2003293376A1 AU 2003293376 A1 AU2003293376 A1 AU 2003293376A1 AU 2003293376 A AU2003293376 A AU 2003293376A AU 2003293376 A AU2003293376 A AU 2003293376A AU 2003293376 A1 AU2003293376 A1 AU 2003293376A1
Authority
AU
Australia
Prior art keywords
cancer treatment
angiogenic compounds
angiogenic
compounds
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003293376A
Other versions
AU2003293376A8 (en
Inventor
Xiaoling Chen
Jacqueline Doody
Yaron Hadari
Alexander Kiselyov
Shawn Ouyang
Evgueni Piatnitski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone Systems Inc filed Critical ImClone Systems Inc
Publication of AU2003293376A1 publication Critical patent/AU2003293376A1/en
Publication of AU2003293376A8 publication Critical patent/AU2003293376A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
AU2003293376A 2002-12-10 2003-12-05 Anti-angiogenic compounds and their use in cancer treatment Abandoned AU2003293376A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43200702P 2002-12-10 2002-12-10
US60/432,007 2002-12-10
US72649603A 2003-12-04 2003-12-04
US10/726,496 2003-12-04
PCT/US2003/038512 WO2004052280A2 (en) 2002-12-10 2003-12-05 Anti-angiogenic compounds and their use in cancer treatment

Publications (2)

Publication Number Publication Date
AU2003293376A1 true AU2003293376A1 (en) 2004-06-30
AU2003293376A8 AU2003293376A8 (en) 2004-06-30

Family

ID=32511622

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003293376A Abandoned AU2003293376A1 (en) 2002-12-10 2003-12-05 Anti-angiogenic compounds and their use in cancer treatment

Country Status (2)

Country Link
AU (1) AU2003293376A1 (en)
WO (1) WO2004052280A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4617299B2 (en) * 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド p38 inhibitors and methods of use thereof
US7932272B2 (en) 2003-09-30 2011-04-26 Eisai R&D Management Co., Ltd. Antifungal agent containing heterocyclic compound
CN101039933B (en) * 2004-09-17 2012-06-06 沃泰克斯药物股份有限公司 Diaminotriazole compounds useful as protein kinase inhibitors
KR101318012B1 (en) * 2004-10-20 2013-10-14 메르크 세로노 에스.에이. 3-arylamino pyridine derivatives
DE102004055998A1 (en) * 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Low molecular weight inhibitors of guanine nucleotide exchange factors of the cytohesin family
WO2006064375A2 (en) * 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
US7829585B2 (en) 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
TWI385169B (en) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd Heterocyclic substituted pyridine derivatives and antifungal agent containing same
JP5131990B2 (en) 2006-01-31 2013-01-30 アレイ バイオファーマ、インコーポレイテッド Kinase inhibitors and methods of use thereof
WO2007123939A2 (en) * 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel arylamino n-heteraryls as mek inhibitors
EA200802050A1 (en) * 2006-04-19 2009-04-28 Лаборатуар Сероно Са NEW HETEROARYLIC-SUBSTITUTED ARYLAMINOPIRIDINE DERIVATIVES AS MEK INHIBITORS
WO2007149395A2 (en) * 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
US8183264B2 (en) 2006-09-21 2012-05-22 Eisai R&D Managment Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
JP5284788B2 (en) * 2006-09-21 2013-09-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 Heteroaryl ring-substituted pyridine derivatives and antifungal agents containing them
US8236823B2 (en) 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
AU2007329480A1 (en) * 2006-12-05 2008-06-12 National Chio Tung University Indazole compounds
DE102007002717A1 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclic indazole derivatives
CA2676163A1 (en) 2007-01-29 2008-08-07 Santen Pharmaceutical Co., Ltd. Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
DE102007022565A1 (en) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclic indazole derivatives
EP2053046A1 (en) 2007-10-26 2009-04-29 Syngeta Participations AG Novel imidazole derivatives
EP2053045A1 (en) 2007-10-26 2009-04-29 Syngenta Participations AG Novel imidazole derivatives
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
GB0806745D0 (en) * 2008-04-14 2008-05-14 Syngenta Participations Ag Novel imidazole derivatives
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
ES2927660T3 (en) 2008-06-16 2022-11-10 Univ Tennessee Res Found Compounds for the treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
DE102008038221A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindole derivatives
DE102008038220A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh oxadiazole
DE102008038222A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carboxylic acid derivatives
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
KR20120130777A (en) * 2010-03-01 2012-12-03 유니버시티 오브 테네시 리서치 파운데이션 Compounds for treatment of cancer
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
JP6456909B2 (en) 2013-03-15 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company LXR regulator
WO2014181287A1 (en) * 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
MX2016014559A (en) 2014-05-06 2018-02-19 Gtx Inc Compounds for treatment of cancer.
WO2017047602A1 (en) * 2015-09-18 2017-03-23 科研製薬株式会社 Biaryl derivative and medicine containing same
IT201600092051A1 (en) * 2016-09-13 2018-03-13 Alessandro Antonelli MEDICAL COMPOUND FOR TREATMENT OF THYROID CANCER
JP6469272B2 (en) * 2017-03-01 2019-02-13 科研製薬株式会社 A pharmaceutical comprising a biaryl derivative or a salt thereof
WO2018204532A1 (en) * 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
AU2018265584B2 (en) * 2017-05-12 2023-09-28 Ludwig-Maximilians-Universität München Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
CN112457306A (en) * 2019-09-06 2021-03-09 上海瑛派药业有限公司 3, 5-disubstituted pyrazole compounds as kinase inhibitors and application thereof
EP4061364A4 (en) * 2019-11-20 2023-09-13 Vivace Therapeutics, Inc. Heteroaryl compounds
US20230089180A1 (en) * 2021-08-13 2023-03-23 Bisichem Co., Ltd. Fused ring heteroaryl compounds and use thereof
CN114044774B (en) * 2021-12-06 2024-04-09 光武惠文生物科技(北京)有限公司 EGFR inhibitor and preparation method and application thereof
CN116041277A (en) * 2023-01-18 2023-05-02 中国药科大学 Phenyl and biphenyl substituted five-membered heterocyclic compound, preparation method, pharmaceutical composition and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320744D0 (en) * 1992-11-04 1993-12-01 Zeneca Ltd Oxa and thiadiazole derivatives

Also Published As

Publication number Publication date
WO2004052280A2 (en) 2004-06-24
AU2003293376A8 (en) 2004-06-30
WO2004052280A3 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
AU2003293376A1 (en) Anti-angiogenic compounds and their use in cancer treatment
AU2003284242A1 (en) Methods and compositions for use in treating cancer
IL172316A0 (en) Novel compounds and their use in therapy
AU2003213144A1 (en) Alkylating agent combinations in the treatment of cancer
IL174994A0 (en) Pyrimidin - 4 - yl - 3, 4 - thione compounds and their use in therapy
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
AU2003209594A1 (en) Quinazoline compounds useful in therapy
IL180278A0 (en) Fused pyrimidones useful in the treatment and the prevention of cancer
IL182652A0 (en) Nitrobenzindoles and their use in cancer therapy
EP1587476A4 (en) Novel compositions and methods in cancer
EP1581542A4 (en) Novel compositions and methods in cancer
AU2003212634A1 (en) Compounds useful in the treatment of cancer
EP1501855A4 (en) Novel compositions and methods in cancer
GB0201498D0 (en) Materials and methods for treating cancer
AU2003274963A1 (en) Mda-7 and free radicals in the treatment of cancer
SG110107A1 (en) Compound and use in treatment
GB0318546D0 (en) Quinoxalinones and their use
EP1583501A4 (en) Novel compositions and methods in cancer
AU2003209459A1 (en) Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
AU2003219664A1 (en) Methods and therapeutic compositions in the treatment of advanced cancer
AU2004281077A1 (en) Methods and agents for the treatment of cancer
AU2002305138A1 (en) Methods and materials for cancer treatment
IL175774A0 (en) Use of siramesine in the treatment of cancer
AU2003246880A1 (en) Alkaloid-derived compounds and use thereof in cancer and malaria treatment
AU2003209265A1 (en) Mrp9 and its use detecting and treating cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase